Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial.

ABSTRACT: Baclofen, a racemic GABA-B (GABA_B) receptor agonist, is commonly used for the management of multiple sclerosis-related spasticity but is associated with frequent dosing and poor tolerability. Arbaclofen, the active R-enantiomer of baclofen, exhibits 100- to 1000-fold greater specificity for the GABA_B receptor compared with the S-enantiomer and ∼5-fold greater potency compared with racemic baclofen. Arbaclofen extended-release tablets have a dosing interval of 12 hours and have shown a favourable safety and efficacy profile in early-phase clinical development. The current Phase 3 study was designed to evaluate the efficacy and safety of arbaclofen extended-release tablets in patients with multiple sclerosis-related spasticity. In this multicentre, double-blind, placebo

SUBMITTER: Okuda DT 

PROVIDER: S-EPMC9732858 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature